Back to targets

Target detail

ADAM9

ADAM metallopeptidase domain 9

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: ADAM metallopeptidase domain 9

Aliases: ADAM9, ADAM metallopeptidase domain 9

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000168615

Index freshness: last_synced_at 2026-05-15T17:54:29.426+00:00 · updated 2026-05-15T17:54:29.824126+00:00

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Live structured evidence · sources

Connectors represented in loaded rows for ADAM9. Empty groups mean no matching rows — not a claim about biology or clinical use.

  • Open TargetsLive when indexed

    Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

  • ChEMBLLive when indexed

    Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).

  • CANTI signal builderLive when indexed

    Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

glioblastoma

literature · opentargets

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

CHEMBL172722

chembl172722

Open drug

CHEMBL368857

chembl368857

Open drug

CHEMBL3648907

chembl3648907

Open drug

CHEMBL173686

chembl173686

Open drug

CHEMBL368205

chembl368205

Open drug

CHEMBL172886

chembl172886

Open drug

CHEMBL4873384

chembl4873384

Open drug

CHEMBL173235

chembl173235

Open drug

CHEMBL3648903

chembl3648903

Open drug

CHEMBL3392650

chembl3392650

Open drug

CHEMBL366034

chembl366034

Open drug

CHEMBL355797

chembl355797

Open drug

CHEMBL4215407

chembl4215407

Open drug

CHEMBL171962

chembl171962

Open drug

CHEMBL4102106

chembl4102106

Open drug

CHEMBL172415

chembl172415

Open drug

CHEMBL173316

chembl173316

Open drug

ILOMASTAT

chembl19611

Open drug

GRASSYSTATIN C

chembl569445

Open drug

CHEMBL171292

chembl171292

Open drug

CHEMBL171986

chembl171986

Open drug

APRATASTAT

chembl206815

Open drug

GRASSYSTATIN A

chembl567893

Open drug

CHEMBL353536

chembl353536

Open drug

CHEMBL433981

chembl433981

Open drug

CHEMBL3966632

chembl3966632

Open drug

CHEMBL3935135

chembl3935135

Open drug

CHEMBL4167357

chembl4167357

Open drug

CHEMBL188414

chembl188414

Open drug

CHEMBL434567

chembl434567

Open drug

CHEMBL3704919

chembl3704919

Open drug

CHEMBL3648905

chembl3648905

Open drug

CHEMBL3941484

chembl3941484

Open drug

CHEMBL173754

chembl173754

Open drug

CHEMBL174014

chembl174014

Open drug

CHEMBL170315

chembl170315

Open drug

CHEMBL170429

chembl170429

Open drug

CHEMBL365261

chembl365261

Open drug

CHEMBL3704903

chembl3704903

Open drug

CHEMBL367710

chembl367710

Open drug

CHEMBL4208519

chembl4208519

Open drug

CHEMBL172249

chembl172249

Open drug

CHEMBL497985

chembl497985

Open drug

CHEMBL173326

chembl173326

Open drug

CHEMBL539171

chembl539171

Open drug

CHEMBL4215451

chembl4215451

Open drug

CHEMBL3648902

chembl3648902

Open drug

CHEMBL366478

chembl366478

Open drug

CHEMBL3704910

chembl3704910

Open drug

CHEMBL172548

chembl172548

Open drug

CHEMBL418655

chembl418655

Open drug

CHEMBL3648893

chembl3648893

Open drug

CHEMBL3897740

chembl3897740

Open drug

CHEMBL425316

chembl425316

Open drug

CHEMBL3643916

chembl3643916

Open drug

CHEMBL172885

chembl172885

Open drug

CHEMBL436049

chembl436049

Open drug

CHEMBL3648906

chembl3648906

Open drug

CHEMBL3648904

chembl3648904

Open drug

CHEMBL177072

chembl177072

Open drug

CHEMBL361087

chembl361087

Open drug

CHEMBL4214929

chembl4214929

Open drug

CHEMBL173027

chembl173027

Open drug

PEPSTATIN

chembl296588

Open drug

CHEMBL3959985

chembl3959985

Open drug

CHEMBL173744

chembl173744

Open drug

CHEMBL4210512

chembl4210512

Open drug

GRASSYSTATIN B

chembl568553

Open drug

Symplostatin 5

chembl2338554

Open drug

CHEMBL4854306

chembl4854306

Open drug

CHEMBL172181

chembl172181

Open drug

CHEMBL3643914

chembl3643914

Open drug

CHEMBL175164

chembl175164

Open drug

CHEMBL174315

chembl174315

Open drug

CHEMBL173846

chembl173846

Open drug

CHEMBL1078396

chembl1078396

Open drug
repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

No matching live evidence found

Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.

CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

Repurposing research signal · APRATASTAT · v0.1

Deterministic research signal for APRATASTAT. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Open signals hub
Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string

No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).

  • chembl: 76
  • opentargets: 1
  • canti_signal_builder: 1
Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

0

Linked drugs

0

Linked in dataset

0

Research signals

0

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review
Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

Repurposing research signal · APRATASTAT · v0.1

Deterministic research signal for APRATASTAT. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

View signals hub